RABIATU BANGURA: Open Payments
NPI 1740903004 · ANNAPOLIS, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,797 in 80 payments from 16 companies in 2025. Trend: 2023 $199 · 2024 $2,469 · 2025 $1,797
Food & beverage: $1,797
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 12 | $303 |
| Lundbeck LLC | 13 | $230 |
| Axsome Therapeutics, Inc. | 6 | $191 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $188 |
| Neurocrine BioSciences, Inc. | 6 | $152 |
| Otsuka America Pharmaceutical, Inc. | 6 | $141 |
| Janssen Pharmaceuticals, Inc | 4 | $106 |
| Vanda Pharmaceuticals Inc. | 3 | $85 |
| Alkermes, Inc. | 3 | $76 |
| Luye Pharma (USA) Ltd. | 2 | $71 |
Products named: COBENFY, Auvelity, CAPLYTA, REXULTI, INGREZZA, ABILIFY ASIMTUFII, INVEGA SUSTENNA, HETLIOZ.
Industry payments across MD — which companies pay providers there.
